Business UpdateJun 9, 2026, 08:46 AM
Palisade Bio to Present on PALI-2108 for Fibrostenotic Crohn's Disease
AI Summary
Palisade Bio announced that its President and Chief Medical Officer, Dr. Mitchell Jones, will present at the New York Academy of Sciences symposium on June 9, 2026. The presentation will focus on fibrostenotic Crohn’s disease (FSCD) and the potential of the company's lead drug candidate, PALI-2108, a locally bioactivated PDE4 inhibitor prodrug. Dr. Jones will discuss the significant unmet need in FSCD, the biological mechanisms of intestinal fibrosis, and preclinical findings supporting PALI-2108's therapeutic approach. PALI-2108 has demonstrated positive results in Phase 1a and two Phase 1b clinical trials and is advancing towards Phase 2 studies.
Key Highlights
- Palisade Bio's CMO, Dr. Mitchell Jones, to present at the New York Academy of Sciences symposium on June 9, 2026.
- Presentation titled "Locally Bioactivated PDE4 Inhibitor Prodrug for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)".
- Discussion will cover the unmet need in FSCD, intestinal fibrosis biology, and PDE4 inhibition.
- The presentation will highlight the scientific rationale supporting PALI-2108, a PDE4 inhibitor prodrug.
- Preclinical findings support PDE4 inhibition for modulating inflammatory and fibrotic pathways in FSCD.
- PALI-2108 has shown positive results in Phase 1a and two Phase 1b clinical trials.
- Palisade Bio is advancing PALI-2108 towards Phase 2 clinical studies in ulcerative colitis and Crohn's disease.
Price Impact
More from PALI